Day 1, Wednesday 31 August 2022

Towards patient-centered research and therapies for neurodegenerative diseases

17:00 – 17:05

Hilal Lashuel, LMNN lab, EPFL

Benjamin Stecher: Chair of the Patient Advisory Group at Rune Labs, Canada

Gina Lupino: Director of intellectual Property and Legal Affairs at TRIUMF Innovations Inc.

Ignacio Muñoz-Sanjuán: Vice President of translational biology, CHDI Foundation

Yves Auberson and Maya Auberson, Switzerland

18:20 – 18:50

Huntington’s disease
Ignacio Muñoz-Sanjuán, Vice President of translational biology, CHDI Foundation

Parkinson’s disease
Simon Stott, Director of Research at Cure Parkinson’s, UK
Gennaro Pagano. Medical Director, Parkinson’s disease, Roche, Switzerland

Alzheimer’s disease
Dirk Beher, CEO, Asceneuron SA, CH Switzerland

19:45 – 20:00

Day 2, Thursday 1st September 2022    

08:15 – 08:30

Hilal Lashuel, EPFL, Switzerland

Glenda Halliday, The University of Sydney, Australia

SESSION 1 : Deconstructing and Reconstructing the Complexity of Proteinopathies

Chairs: Efthymia Vokali and Hilal Lashuel

Steve Finkbeiner, Gladstone Institutes / University of California, San Francisco, USA

Adriano Aguzzi, USZ, Institute of Neuropathology, Switzerland

12:30 – 13:00

Hilal Lashuel and Adriano Aguzzi

SESSION 2 : The structural landscape of pathological aggregates

Chairs: Melissa Murray and Laura Gasparini

Sjors Scheres, Cambridge Biomedical Campus, United Kingdom

Roland Riek, ETH Zurich, Switzerland

15:45 – 16:10

Chairs and speakers

SESSION 3 : New tools and approaches to capture the molecular diversity of pathological aggregates and elucidate their role in disease pathogenesis

Chairs: Laura Parkkinen and Steve Finkbeiner
17:50 – 19:30

Chairs and speakers

Day 3, Friday 2 September 2022    

09:00 – 09:40

Structure-based discovery of small-molecules that disassemble tau fibrils of Alzheimer's disease.

David Eisenberg, University of California UCLA, USA

SESSION 4 : Progress towards developing PET imaging tracers

Chairs: Celia Dominguez and David Eisenberg

Ignacio Muñoz-Sanjuán, CHDI Foundation, USA

Bradford Navia, APRINOIA THERAPEUTICS LLC, USA

12:10 – 12:40

Chairs and speakers

SESSION 5 : Reverse Engineering the pathology of neurodegenerative diseases

Chairs: Wilma van de Berg and Henning Stahlberg

Magdalini Polymenidou, University of Zurich, Switzerland

Jens Christian Schwamborn, University of Luxembourg, Luxembourg

SESSION 6 : System-based approaches to deciphering the genetic, molecular, and structural determinants of pathology formation in neurodegenerative diseases

Chairs : Steve Finkbeiner and Hilal Lashuel

Judith Steen, Boston Children's Hospital / Harvard Medical School, USA